Drug intelligence / Profile preview

JD004

Development stage: Preclinical
Lead developer: Beijing Jingda Biotechnology
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

JD004 is an investigational natural killer (NK) or chimeric antigen receptor natural killer (CAR-NK) cell therapy being developed by Jingda Biotechnology. The therapy is designed to leverage immunologic cytotoxicity and NK cell replacement mechanisms to target and destroy cancer cells. It is currently in the discovery phase of development, with a primary focus on the treatment of metastatic breast cancer (MBC).

Beyond the preview

Go deeper on JD004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JD004.

Explore the full profile